News / New funding allows food specialist Silo to aim higher and expand

first_img Perishable food supply chain start-up Silo has raised $9m in a second fundraising.In a little more than 18 months, the San Francisco-based firm has developed a cloud-based platform for growers, distributors and suppliers in the perishable food system, with tools based on machine learning technology that automate operations and manage relationships for buyers and sellers.The company has focused on the US domestic market, mostly on the west coast, but co-founder and CEO Ashton Braun told The Loadstar this week the new investment would allow it to start working on international shipments.“We have partners now helping us to understand how the business works and we will build the capability for international shipments into the platform in the coming months.“There is food waste at every level of the supply chain and everyone is looking to get smarter,” he said.However, he added that the more immediate future would see new offices in New York and Los Angeles and engineering staff hired to support the development of financial services and logistical tools.“Eliminating inefficiencies in the food system is crucial, especially in these uncertain times. We’re thrilled to have the support of an amazing group of investors to help us grow Silo’s business to new categories and markets,” said Mr Braun.The funding round was led by Andreessen Horowitz (a16z), with additional participation from existing investors Initialized Capital and Haystack Ventures. Anish Acharya, a general partner at a16z who focuses on financial services, has joined Silo’s board.He said: “The market potential for an innovator like Silo to reduce waste and improve margins is enormous, and we’re excited to support its efforts as the system of record for food distribution in the United States.“Silo is well-positioned to scale beyond the west coast to help more customers modernise and transition their operations from pen and paper to software,” he added. By Gavin van Marle 25/09/2020last_img read more

Inside the impossibly byzantine world of prescription drug prices

first_img When Martin Shkreli’s Turing Pharmaceuticals hiked the price of its anti-parasitic drug to $750 a pill, there was public outcry. So Turing and its backers resorted to a talking point employed across the drug industry: That was the list price. Nobody actually pays that.Forgive the confusion. Even for people whose job requires them to know this stuff, drug pricing is hopelessly complex. That helps explain why, for all the debate over drug costs these days, there’s surprisingly little detail about what anybody actually is paying for prescription medicines.“We have list prices, wholesale prices, average wholesale prices, rebates, supplemental rebates, mark-ups, outpatient vs. inpatient, formularies, patent expirations,” Andy Slavitt, acting administrator at the federal Centers for Medicare and Medicaid Services, said at a forum in Washington last month. “Most of that information is not available or well understood by the public.”advertisement Under siege over prices, drug makers ready their counterpunch Tags drug pricespharmaceutical industryprescription drugs BusinessInside the impossibly byzantine world of prescription drug prices The system of determining prescription drug prices is hopelessly complex and little understood by the public. Andreas Rentz/Getty Images By Dylan Scott Dec. 21, 2015 Reprints This all raises the question: Just what the heck is the point of the list price anyway? Related: The short answer is that the list price is a drug company’s opening bid in negotiations with the insurance plans, government programs, and health care providers that purchase its medicines.advertisement Related: Drug makers and insurers, longtime rivals, eye an alliance on prices But the reality of drug prices can be almost impossible to understand.For starters, the negotiations between health plans and pharmacy-benefits managers or health plans that take a list price down to its actual cost are totally hidden from public view. Even their outcome, the final price paid, often isn’t known.“It emerges in a completely different form, and most of us can’t see what’s happening inside this black hole,” said Dr. Walid Gellad, a University of Pittsburgh professor who studies drug prescribing. “It’s impossible to understand what people are really paying.”That means that a drug’s real cost — the elusive lower price that drug makers love to cite as proof that list prices are misleading — is not typically public.Some aggregate estimates have been made to understand the difference between list prices and net prices. An IMS Health analysis released last month estimated that while list prices increased on average by 13.5 percent in 2014, the net price increase was 5.5 percent.That would seem to back up the drug industry’s position — but that analysis was based in part on proprietary information not available to the public. And even so, according to a new Bloomberg analysis, the United States still pays more for drugs than other countries once those discounts are accounted for.Equally frustrating for those who track the issue is that it’s hard to know exactly how a drug maker goes about setting a list price in the first place.“Right now, it’s a black box,” said Dan Ollendorf, chief review officer at the Institute for Clinical and Economic Review. “There’s really no inkling to the general public about what the ingredients of that soup that make up the price that’s set.”Read more: Anger over drug prices driving support for Democrats’ ideasThe exact equation is unknown, but some of the variables are obvious, said Khedkar, the consulting executive.The big one: competition. Drug makers consider other drugs that are already on the market or coming soon. Then they look at the market control of the various payers they’re working with. Medicaid is a not-for-profit venture; health insurance plans are. They require different approaches.Lastly, what are the long-term projections for the drug? A medicine usually starts with a limited number of uses, but over time, its so-called “off-label” indications expand. So down the road, the price might go down, but if the drug is going to be prescribed to more people for more purposes, that is another factor a drug maker may take into account.A recent investigation by the Senate Finance Committee into the pricing of Gilead’s hepatitis C drug, Solvaldi, is one of the few times that a drug company’s thinking behind a list price has been documented in such detail.Gilead executives weighed whether the expanding Medicaid population under the Affordable Care Act and more baby boomers joining Medicare should factor into its pricing strategy because the required discounts for the government programs tend to drive actual prices paid down.They also looked at the discounts previously given to private payers for prior hepatitis C treatments and considered what the Solvaldi price would mean for future medicines. A second-wave drug, Harvoni, was in the works, and Gilead knew that the Solvadi price would determine what the company could charge for its follow-up.Gilead also considered whether to contract with health plans, and a big part of that equation was the plans’ market share. Plans with large control of their markets were the ones who could block Solvaldi because of its high price. In its final round of pricing discussions, the report said, the company sought the maximum price it could set without risking that a substantial number of payers or physicians would not take to the drug.“This presentation shows that Gilead set a price as high as it thought acceptable before significant access restrictions would be imposed,” the report said.The final price? $84,000. “The list price helps establish that initial starting point,” said Pratap Khedkar, a top executive at ZS Associates, a consulting firm that advises drug companies. “If you’ll never let me increase the price in the future, I’ll start high and I’ll drop as much as I need to.”In other words, the list price is not dissimilar from sticker prices on new cars, as another expert put it to STAT.The actual price is driven down as health plans and pharmacy-benefits managers negotiate with drug makers. Government programs like Medicare and Medicaid also have built-in discounts that pharma companies must honor if they want those customers.Despite all of that, the list price is what usually drives headlines.“I think there’s oftentimes a perception issue when it’s looked at just as list-price increases,” Lori Reilly, a top official at the Pharmaceutical Research and Manufacturers of America, the pharmaceutical industry’s Washington lobby, told STAT earlier this year. “The perception and reality aren’t necessarily aligned on some of these issues.”last_img read more

Kansas lawmakers fail to override veto of Medicaid expansion

first_img STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Kansas lawmakers fail to override veto of Medicaid expansion GET STARTED Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED TOPEKA, Kan. — Kansas won’t be extending its health coverage to thousands of poor adults under former President Barack Obama’s signature health care law after Democrats and moderate Republicans failed Monday to override conservative GOP Gov. Sam Brownback’s veto of an expansion bill.The state House voted 81-44 to override Brownback’s veto of the measure, which would have expanded the state’s Medicaid program to cover as many as 180,000 additional adults. But supporters of the bill needed three more votes, or 84 in the 125-member chamber, for the two-thirds majority necessary to overturn the governor’s action. Log In | Learn More Kansas Gov. Sam Brownback vetoed a bill that would have expanded the state’s Medicaid program. Orlin Wagner/AP What is it? What’s included? By Associated Press April 3, 2017 Reprints Associated Press Politics About the Author Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Tags Medicaidpolicylast_img read more

Regeneron wasn’t paying ‘kickbacks.’ It was helping people pay egregious Medicare copays

first_img Please enter a valid email address. Kristoffer Tripplaar/Sipa via AP Last Wednesday, the Department of Justice filed suit against Regeneron for paying ” tens of millions of dollars in kickbacks” through a foundation that helps patients cover copays associated with Eylea, its macular degeneration drug. Whether or not Regeneron broke the law, the suit illuminates the stupidity, cruelty, and counterproductivity of Medicare’s insistence that patients feel financial pain in order to receive medically necessary therapies.Let’s start with what Regeneron is accused of doing, because the term kickbacks conjures up notions of shady, back-room corruption. Was Regeneron paying doctors on the sly to prescribe Eylea over the competition? No. Was it paying doctors to prescribe Eylea for patients who didn’t need it? No. Was Regeneron delivering bags of cash to Medicare patients? Wrong again. Sending them to fancy Caribbean resorts to get treatments and sticking Medicare with the tab from the swim-up pool bar? Still no.Here’s what Regeneron did: It donated money to a nonprofit patient assistance foundation — a disappointingly necessary and common practice — so the foundation could help patients afford their copays on a medically necessary treatment that staves off blindness. Regeneron was, essentially and entirely, simply paying Medicare.advertisement By Peter Kolchinsky June 30, 2020 Reprints Tags legalMedicare Related: Pfizer sues Trump administration over anti-kickback rules, saying they prevent it from helping lower seniors’ drug costs  Leave this field empty if you’re human: Until we eliminate out-of-pocket costs, we should not only allow drug companies to cover those costs, we should encourage them to do it. Regeneron should be able to cover the Eylea copays; Genentech can cover the Lucentis copays. Patients should get whatever drug their doctor says is best for them without having to worry about which one is unaffordable.Market forces are still at play — companies are incentivized to have the best drug so more doctors will want to prescribe it. When two drugs are similar enough, insurance plans play them off one another to get rebates and require patients to at least try the less expensive drug first. There are many cases when that is medically acceptable. When it isn’t, it is not conscionable in America to reserve the better drug only for those who can pay. For many patients, Eylea is indeed the best drug. To make it inaccessible to poorer patients because they can’t afford the copay is to condemn them to get more injections in their eyes and/or to progress towards blindness. Regeneron’s so-called kickbacks are just leveling the playing field between rich and poor.Not everyone sees it that way. Sen. Elizabeth Warren (D-Mass.) has argued that patient assistance programs only “mask” drug prices that are too high. Warren says companies should instead make their drugs affordable by lowering prices. But a patient’s $6,000 deductible is set by insurance and stays the same whether a drug costs $20,000 or $10,000. Warren’s argument betrays a profound ignorance of the cost of biomedical innovation and of the rot endemic to America’s insurance system.Factoring in all the money-losing drug development companies, the drug industry’s overall profit margins are 10% to 12%. Lowering all drug costs by even 30% would decimate the industry. Yet cutting Eylea’s price by 30% would not reduce a patient’s deductible and therefore would make it no more affordable. Warren knows better. She is pandering to a public taught to hate the drug industry and looking for easy solutions.The easy solution is to make America’s insurance function like actual insurance by reducing out-of-pocket costs so patients can afford drugs their physicians prescribe.As for making sure that America doesn’t overpay, consider that drugs go generic (or in Eylea’s case, biosimilar). As manufactured goods, when their patents expire, competitors step in and compete on price. No other aspect of health care has this built-in price control. The end of a drug’s patent-protected branded period is akin to the end of a mortgage; America takes ownership of a public good. That’s the price control we’ve long relied on since the Hatch-Waxman Act of 1984. That’s the price control we should continue to turn to so America can continue building its armamentarium of inexpensive, generic drugs that serve us forever.Until we eliminate out-of-pocket costs, if helping patients afford medically necessary and FDA-approved drugs is a kickback, so be it. It only reflects well on the word. But what Medicare is doing to patients is kicking them in the face.Peter Kolchinsky is a biotechnology investor and scientist, managing partner of RA Capital Management, L.P., and author of “The Great American Drug Deal” (Evelexa Press, 2020). At the time of publication, neither the author nor RA Capital have investments or other financial relationships with Eylea or Regeneron. About the Author Reprints First OpinionRegeneron wasn’t paying ‘kickbacks.’ It was helping people pay egregious Medicare copays Put aside for a minute that physicians prescribed Eylea for these patients. Or that using Eylea instead of Lucentis or off-label, compounded Avastin (a chemotherapy drug) typically results in fewer visits to the ophthalmologist and fewer injections of drug into the eye. Or that for patients with severe diabetic macular edema, another degenerative condition that leads to blindness, an NIH-sponsored trial demonstrated that Eylea is more effective than Lucentis and Avastin (let alone that compounding Avastin risks introducing an infection into a patient’s eye).Instead, let’s focus on the copays themselves. In announcing the complaint, the U.S. attorney’s office in Massachusetts says that Medicare copays “encourage market forces to serve as a check on health care costs.” That sounds rational enough. But consider that Eylea is hardly the kind of treatment any patient would want unless they really needed it (it’s injected in the eye!). And consider that Medicare would charge a copay for a medicine even when there are no alternative treatments.So what is this copay “encouraging” or nudging patients to do? The answer is simple: It makes someone think, “Do I really need this treatment?” The copay is there so you don’t “overuse” services your insurer (in this case Medicare) has to pay for.Any time a patient avoids a drug because she or he cannot afford Medicare’s required copayment, Medicare has failed to insure that patient. The U.S. government has failed that patient, charging taxes for empty promises.Congress knows that Medicare charges excessive out-of-pocket costs. Members of Congress have generated many bills calling for lowering those costs. But until those reforms are instituted, it’s high time someone challenged Medicare’s heartless and senseless anti-kickback rules. On the heels of the Regeneron’s lawsuit, Pfizer did just that, filing a lawsuit against the Trump administration on Friday arguing that Medicare’s policy is unconstitutional.I’ll add that it’s just plain dumb.We should all back legislation that caps or ideally eliminates such cruel cost-sharing. Insurance premiums are how we all share in the cost of caring for the few of us who need medical treatment today. Cost-sharing really means less insurance, which actually means less sharing. The alleged lawbreaking here is that Regeneron provided enough cash to the foundation only to cover the total copays associated with Eylea prescriptions — it did not provide enough to also cover the copays for a competing drug, Lucentis, made by Genentech. That is how Regeneron falls afoul of the Anti-Kickback Statute, and that’s where it allegedly stepped over the line.advertisement Peter Kolchinsky For patients with private insurance, drug companies provide copay assistance directly. Usually this assistance is in the form of a coupon or charge card designed specifically to reduce the patient’s out-of-pocket costs to something manageable. That practice is legal, though it’s unfortunate that our gap-riddled insurance system makes it necessary. But Medicare, which provides insurance for people over 65, doesn’t allow this kind of copay assistance. Instead, it requires that a charity serve as a go-between, a fig-leaf of bureaucracy. So Regeneron donated money to a charity so it could help patients pay Medicare’s egregiously high out-of-pocket costs. Privacy Policy [email protected] Newsletters Sign up for Pharmalot Your daily update on the drug industry.last_img read more

Talking Sport Podcast: Road trip to Ulster, relegation battles and club games are back

first_img WhatsApp Facebook SEE ALSO – Check out the dedicated podcast section on LaoisToday Facebook Twitter Pinterest Talking Sport Podcast: Road trip to Ulster, relegation battles and club games are back Here are all of Monday and Tuesday’s Laois GAA results Laois County Council granted almost €500,000 from Additional Outdoor Infrastructure Fund By LaoisToday Reporter – 10th June 2021 RELATED ARTICLESMORE FROM AUTHOR Previous articleThree Laois employees take on Malin to Slea Head cycle in aid of DEBRA IrelandNext articleLaois people have Covid-19 vaccine appointments in Dublin cancelled following ‘system glitch’ LaoisToday Reporter center_img GAA And all of a sudden there is more GAA games than we can keep up with.All four Laois adult county games are in action this weekend as well as the return of club league games, outstanding 2020 championship fixtures and underage county finals.Steven and Alan are back with this week’s LaoisToday Talking Sport Podcast to look ahead to the Laois footballers relegation playoff against Down, the hurlers clash with Antrim, the ladies football Division 3 semi-final and a camogie relegation game.Can the Laois footballers survive in Division 2? Are the hurlers heading in the right direction? What can they learn from Kilkenny game?You can listen to the latest episode in full below on Soundcloud or by subscribing on Apple Podcasts or Spotify. Electric Picnic WhatsApp Home Podcasts Sports Podcast Talking Sport Podcast: Road trip to Ulster, relegation battles and club games… PodcastsSports Podcast TAGSTalking SportTalking Sport Podcast Community Pinterest Twitter Electric Picnic receives €423,000 funding under Live Performance Support Schemelast_img read more

Horizons to close managed futures ETF

first_imgIE Staff Companies Horizons ETFs Management (Canada) Inc. Horizons ETFs Management (Canada) Inc. announced Friday it will be terminating Horizons Auspice Managed Futures Index ETF at the close of business on March 28.Effective immediately, no further direct subscriptions for units of the ETF will be accepted, Horizons says in a news release. Share this article and your comments with peers on social mediacenter_img Horizons expects March 22 to be the last date on which a redemption request may be placed with the manager.The ETF is expected to be de-listed from the Toronto Stock Exchange at the close of business on or about March 23, Horizons says, with all units still held by investors subject to a mandatory redemption.Any remaining unitholders of the ETF as of March 28 will receive the net proceeds from the liquidation of the assets, less all liabilities and all expenses incurred in connection with the dissolution of the ETF, on a pro-rata basis. Facebook LinkedIn Twitterlast_img read more

Ministry Says Magna Card is Good for Business

first_imgRelatedMinistry Says Magna Card is Good for Business FacebookTwitterWhatsAppEmail Permanent Secretary in the Ministry of Industry, Investment, and Commerce, Reginald Budhan has lauded the Magna Customer Rewards Programme, and is encouraging more of this type of initiative to boost consumer spending.“Within the context of the global recession and its adverse impact on the economy, any means of reducing prices for consumers and stimulating demand, is good for the economy,” Mr. Budhan said.“As we know, in times of recession, consumers tend to guard their dollars. That leads to reduction in sales and contraction in companies, jobs are cut and less disposable income is available,” he explained.“I am pleased that companies such as Magna Rewards are seeking new ways of easing the burden on consumers and, simultaneously, increasing the demand for goods and services,” he stated.Permanent Secretary in the Ministry of Industry, Investment and Commerce, Reginald Budhan (right), speaking with Managing Director of Toyota Jamaica, John Connell, at a press conference held Tuesday (September 1) at the Courtleigh Hotel, New Kingston, to announce six new partners in the Magna Rewards Programme.Mr. Budhan was speaking at a press conference hosted by the Magna Customer Rewards Programme, at the Courtleigh Hotel, New Kingston on September 1. The event marked the addition of six new partners to the programme, which currently has over 700,000 cardholders and 220 partner locations in the island.Representatives of the six companies all praised the programme as a positive one, indicating that it had helped to improve sales, as well as forge closer relationships with customers. They also considered it as an effective means of giving back to their customers.The new partners were: Toyota Jamaica; Caledonia Medical; Eyeland Eyewear; St. Thomas Farm Store; Simartsoft, and the University College of the Caribbean (UCC).Magna rewards is an electronic card-based loyalty programme designed to reward loyal customers of participating partners in a meaningful way. It offers customers free bonus points with every purchase, when shopping at identified partner locations. The programme is the first of its kind in the island, and is a member of the Neal and Massy group of companies. RelatedMinistry Says Magna Card is Good for Business Advertisementscenter_img RelatedMinistry Says Magna Card is Good for Business Ministry Says Magna Card is Good for Business CommerceSeptember 2, 2009last_img read more

NSW Government Funds Summer Activities For Regional Youth In Hard Hit Communities

first_imgNSW Government Funds Summer Activities For Regional Youth In Hard Hit Communities Young people in communities hit hardest by the impacts of drought, bushfire and COVID-19 border closures will enjoy a mix of free and subsidised activities this summer, with the help of funding from the NSW Government.Deputy Premier and Minister for Regional NSW John Barilaro, Minister for Regional Youth Bronnie Taylor and Acting Minister for Sport and Minister for Skills Geoff Lee today announced the Summer Break program for Regional Youth.Mr Barilaro said after a challenging year, young people in 51 local government areas across the state will be able to participate in sports and recreation camps, short-courses, barbecue and beats disco events or enjoy extended opening hours at council facilities over the summer.“While much of regional NSW is on track for recovery, a number of communities are still coming to terms with the fallout of bushfires, COVID border closures or enduring impacts of drought so I know this announcement will be welcome news for families,” Mr Barilaro said.“Up to $10,000 will be made available to impacted councils to cover the costs of running youth events or to extend youth services between 16 December 2020 and 4 February 2021, while a share in a fund worth $85,000 will allow approximately 20 PCYCs in affected towns to run Barbecue and Beats discos.”Mrs Taylor said the initiative follows the NSW Government’s successful Drought Break program which was launched in December 2019 to support young people in more than 30 drought-affected communities in the state’s central, north and far west regions.“I have heard first-hand the overwhelmingly positive feedback from last year’s Drought Break program which first came to life with the help of the Regional Youth Taskforce and brought together kids, parents, carers and wider communities to have fun,” Mrs Taylor said.“I’m thrilled to confirm further funding to bring back this brilliant initiative that will give regional youth a fair opportunity to relax and enjoy themselves throughout summer.”Mr Lee said the NSW Government will provide more than 500 free places for young people at 14 camps to enjoy activities such as archery, kayaking and cooking craft with meals and accommodation included and free transport provided.“Last year’s free sport and recreation camps were really popular for hundreds of young people in drought communities and I know this year will be no different,” Mr Lee said.“The popular Summer Skills program has returned with opportunities for 15 to 24 year olds in health, construction, business, agribusiness, hospitality and retail.”Visit www.nsw.gov.au/summeractivities /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Australia, Border, bushfires, business, coronavirus, council, covid-19, drought, Government, Minister, NSW, nswpol, Premier, running, Skills, sports, visit, Youthlast_img read more

Working toward conflict prevention through protection of minority rights: Africa-Middle East Regional Forum

first_imgWorking toward conflict prevention through protection of minority rights: Africa-Middle East Regional Forum OHCHRThe Africa-Middle East Regional Forum on conflict prevention and the protection of the human rights of minorities, convened by the UN Special Rapporteur on minority issues Fernand de Varennes, will take place on 15 and 16 June.Hosted by the Government of The Gambia, the Regional Forum will bring together over 200 minority participants and State representatives, as well as UN, regional organisations representatives and minority and civil society groups. Registration for the event is open until 11pm CEST, 9 June.The Africa-Middle East Regional Forum is the second of four regional fora convened in 2021 on maintaining peace through justice and human rights for minorities, and will consider how addressing the grievances which are often at the root of most of the world’s conflicts today is a significant approach to the prevention of violent conflicts. Discussions will inform the work and recommendations of the 14th session of the global UN Forum on Minority Issues taking place in Geneva in December 2021 also on the theme of “Conflict Prevention and the Protection of the Human Rights of Minorities”.The Africa-Middle East Regional Forum will take place on-line this year because of the pandemic and is open to the media. The event will be livestreamed at: https://www.youtube.com/channel/UC4nFioBnLPu3b2ZufJGtD1wLearn more about the speakers and the schedule of the Africa-Middle East Regional Forum on Minority Issues. /Public Release. This material comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here. Why?Well, unlike many news organisations, we have no sponsors, no corporate or ideological interests. We don’t put up a paywall – we believe in free access to information of public interest. Media ownership in Australia is one of the most concentrated in the world (Learn more). Since the trend of consolidation is and has historically been upward, fewer and fewer individuals or organizations control increasing shares of the mass media in our country. According to independent assessment, about 98% of the media sector is held by three conglomerates. This tendency is not only totally unacceptable, but also to a degree frightening). Learn more hereWe endeavour to provide the community with real-time access to true unfiltered news firsthand from primary sources. It is a bumpy road with all sorties of difficulties. We can only achieve this goal together. Our website is open to any citizen journalists and organizations who want to contribute, publish high-quality insights or send media releases to improve public access to impartial information. You and we have the right to know, learn, read, hear what and how we deem appropriate.Your support is greatly appreciated. All donations are kept completely private and confidential.Thank you in advance!Tags:Africa, conflict, Gambia, Geneva, Government, Human, Human Rights, justice, Media, Minorities, OHCHR, pandemic, participants, prevention, Society, UN, worldlast_img read more

GM trashes the Equinox and Terrain diesel engines for 2020

first_img See More Videos Thanks to the misdeeds of a few automakers, diesel-powered engines are currently enjoying the popularity of toothpaste-flavoured ice cream.This excepts large-and-in-charge pickup trucks, of course, as prodigious oil-burning torque remains the choice for getting work done. In the mainstream, however, it’s definitely fading from public consciousness.Chalk up another cancellation to market demand, then, as Chevy will not be renewing the diesel engine option in the Equinox crossover for the 2020 model year. Trending Videos Buy It! Princess Diana’s humble little 1981 Ford Escort is up for auction An engagement gift from Prince Charles, the car is being sold by a Princess Di “superfan” COMMENTSSHARE YOUR THOUGHTS We encourage all readers to share their views on our articles using Facebook commenting Visit our FAQ page for more information. The Rolls-Royce Boat Tail may be the most expensive new car ever The diesel was available in these crossovers for a couple of years, producing only 137 horsepower but a healthy 240 lb.-ft. of torque. It was paired with a six-speed automatic, a ‘box which possibly explains its relatively meh real-world fuel economy, even though Chevy advertises an efficiency of 6.0 L/100 km on its Canadian website. RELATED TAGSChevroletEquinoxGMCTerrainSUVNon-LuxuryNew VehiclesDieselequinoxNon-Luxuryterrain advertisement ‹ Previous Next › Created with Raphaël 2.1.2Created with Raphaël 2.1.2 2018 Chevrolet Equinox Premier Diesel AWD PlayThe Rolls-Royce Boat Tail may be the most expensive new car everPlay3 common new car problems (and how to prevent them) | Maintenance Advice | Driving.caPlayFinal 5 Minivan Contenders | Driving.caPlay2021 Volvo XC90 Recharge | Ministry of Interior Affairs | Driving.caPlayThe 2022 Ford F-150 Lightning is a new take on Canada’s fave truck | Driving.caPlayBuying a used Toyota Tundra? Check these 5 things first | Used Truck Advice | Driving.caPlayCanada’s most efficient trucks in 2021 | Driving.caPlay3 ways to make night driving safer and more comfortable | Advice | Driving.caPlayDriving into the Future: Sustainability and Innovation in tomorrow’s cars | Driving.ca virtual panelPlayThese spy shots get us an early glimpse of some future models | Driving.ca Gearheads over at The Car Connection were told by Chevy spox earlier this week that the engine won’t return thanks to poor demand.A quick check of the Canadian fleet order guide for General Motors confirms this decision will carry over to this country as well. In addition to binning the 1.6-litre turbo-diesel for 2020, the trim levels of 3LT and 3LZ will also vanish.The usual colour-naming dance is also being performed, with some shades like Orange Burst being swapped out for the likes of Cayenne Orange. A fresh Midnight Edition murders out all the chrome, while content that was once part of a Driver Confidence Plus package is now standard equipment.In case you’re wondering, the GMC sales staff across the showroom also have one less diesel engine in their catalog. The 2020 fleet guide spells out deletions for the GMC Terrain, erasures which include the turbo-diesel. Minor trim and equipment changes are also on tap for the upcoming model year. These changes are reflected on the American fleet guide as well. Trending in Canadalast_img read more